ARM-ED: Advanced Respiratory Monitoring Events in Drug Toxicity
Study Details
Study Description
Brief Summary
There is a drug-related death crisis in Scotland. The majority of these deaths have involved the misuse of opiates (e.g. heroin) and benzodiazepines (e.g. valium) which cause an individual to stop breathing. The Advanced Respiratory Monitoring Events in Drug Toxicity (ARM-ED) study is a study investigating whether a wearable sensor can help detect problems with breathing in patients who have had drugs or medications that may cause this effect. The study will span a year and will study two groups of patients - those who attend with actual or expected respiratory depression secondary to acute drug toxicity and individuals who have undergone procedural sedation and analgaesia in the Emergency Department.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study aims to assess if it is feasible to collect respiratory waveform data using an advanced respiratory monitoring device named Pneumowave and whether the device is user friendly in terms of nurse, clinician, and patient.
This is an observational cohort study which utilises passive non-invasive data collection. The device, Pneumowave, will be studied in two distinct groups of patients: those who attend with actual or expected respiratory depression secondary to acute drug toxicity (Group 1) and individuals who have undergone procedural sedation and analgaesia (PSA) in the ED (Group 2). Participants will be studied for the duration of their ED attendance or in the case of PSA for the duration of their sedation and recovery period. They will be followed up via electronic notes 28 days later to identify adverse outcome and to link cases to available toxicology screens performed.
The target number of participants in this study is 100. 50 patients who fit group 1 characteristics and 50 patients who fit group 2 characteristics.
Data from Pneumowave will be analysed in parallel with de-identified clinical and vital sign observational data to inform artificial intelligence driven predictive modelling algorithms.
This study will inform on the utilisation and usability of a wearable device for monitoring an individual's respiratory patterns following the effects of sedative drug use. It will add understanding to potential use of such a device to predict the respiratory compromise in the wearer and alert appropriate stakeholders for timely intervention and ultimately prevention of the wearer's morbidity and mortality.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| ARM-ED group 1 - Acute toxicity group Patients attending the Emergency Department with acute sedating drug toxicity |
Device: Pneumowave Device placement and data capture
Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.
Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,
|
| ARM-ED group 2 - PSA group Patients undergoing procedural sedation and analgaesia in the Emergency Department |
Device: Pneumowave Device placement and data capture
Participants in the acute toxicity group will be studied for a period of time during their Emergency Department attendance or in the case of PSA for the duration of their sedation and recovery period.
Usual care will be provided to the patient with additional period with Pneumowave biosensor placed onto chest and data capture for a period of time whilst patient is in the Emergency Department,
|
Outcome Measures
Primary Outcome Measures
- Length of time device in situ on patient [1 year]
Absolute length of time device in situ on patient and as proportion of intended length of time of device data capture.
- Number of times device removed by patient / other [1 year]
Number of times device removed total during each study episode.
- Proportion of waveform data collected while in situ [1 year]
Length in time of waveform data collection as proportion of intended length of time of device data capture.
Secondary Outcome Measures
- Observation of waveform data from Pneumowave device [Duration of study period, up to 15 months]
Observation of waveform data from Pneumowave device and compare to: Normal care vital signs Continuous monitoring vital signs extracted from patient monitors
- Compare Pneumowave respiratory wave patterns to clinical events [Duration of study period, up to 15 months]
Compare Pneumowave respiratory wave patterns to clinical events: Normal respiratory patterns Clinical deterioration Interventions in ED
- Compare respiratory waveform patterns and motion artefact data [Duration of study period, up to 15 months]
Compare respiratory waveform patterns and motion artefact data to: GCS Richmond Agitation-Sedation Scale (RASS)
Eligibility Criteria
Criteria
Inclusion Criteria:
Group 1 - Acute toxicity group
-
Presentation to ED due to presumed overdose of drug with potential for respiratory depression (intentional, accidental, recreational, therapeutic excess)
-
At least one of GCS <15 or respiratory depression or risk of deterioration of GCS or respiration.
-
Age >16 years
-
Are willing and able to give informed consent or have available next of Kin to provide informed consent on the participant's behalf
-
Able (in the Investigators opinion) and willing to comply with all study requirements
Group 2 - PSA group
-
Patient undergoing procedural sedation and anaesthesia in ED
-
Age >16 years
-
Are willing and able to give informed consent
-
Able (in the Investigators opinion) and willing to comply with all study requirements
-
Can speak and read English
Exclusion Criteria:
Group 1 - Acute toxicity group
-
Unable to provide consent and no next of kin to provide consent on participant's behalf
-
Impaired consciousness / respiratory suppression most likely due to cause other than acute drug use
-
Condition primarily related to alcohol use and no evidence of acute drug use
-
Condition due to withdrawal of drugs / alcohol.
-
Treating clinician deems patient inappropriate to be included in study
Group 2 - PSA group
-
Unable to provide consent
-
Treating clinician deems patient inappropriate to be included in study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Emergency Department, Queen Elizabeth University Hospital | Glasgow | United Kingdom | G51 4FT |
Sponsors and Collaborators
- NHS Greater Glasgow and Clyde
- Pneumowave Ltd
Investigators
- Principal Investigator: David J Lowe, MBChB BMSc FRCEM, NHS Greater Glasgow and Clyde
Study Documents (Full-Text)
None provided.More Information
Publications
- Bird SM, McAuley A. Scotland's National Naloxone Programme. Lancet. 2019 Jan 26;393(10169):316-318. doi: 10.1016/S0140-6736(18)33065-4.
- Chu M, Nguyen T, Pandey V, Zhou Y, Pham HN, Bar-Yoseph R, Radom-Aizik S, Jain R, Cooper DM, Khine M. Respiration rate and volume measurements using wearable strain sensors. NPJ Digit Med. 2019 Feb 13;2:8. doi: 10.1038/s41746-019-0083-3. eCollection 2019.
- Community Management of Opioid Overdose. Geneva: World Health Organization; 2014.
- EMCDDA (2018) Preventing overdose deaths in Europe.
- EMCDDA. Drug-related deaths and mortality in Europe. Update from EMCDDA expert network July 2019. Available from https://www.emcdda.europa.eu, accessed 09/02/2020
- Giglio RE, Li G, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol. 2015 Dec;2(1):10. Epub 2015 May 22.
- Holland KM, Jones C, Vivolo-Kantor AM, Idaikkadar N, Zwald M, Hoots B, Yard E, D'Inverno A, Swedo E, Chen MS, Petrosky E, Board A, Martinez P, Stone DM, Law R, Coletta MA, Adjemian J, Thomas C, Puddy RW, Peacock G, Dowling NF, Houry D. Trends in US Emergency Department Visits for Mental Health, Overdose, and Violence Outcomes Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2021 Apr 1;78(4):372-379. doi: 10.1001/jamapsychiatry.2020.4402.
- Leino K, Mildh L, Lertola K, Seppälä T, Kirvelä O. Time course of changes in breathing pattern in morphine- and oxycodone-induced respiratory depression. Anaesthesia. 1999 Sep;54(9):835-40.
- McDonald R, Campbell ND, Strang J. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation. Drug Alcohol Depend. 2017 Sep 1;178:176-187. doi: 10.1016/j.drugalcdep.2017.05.001. Epub 2017 May 25. Review.
- McDonald R, Strang J. Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016 Jul;111(7):1177-87. doi: 10.1111/add.13326. Epub 2016 Mar 30. Review.
- Medical research Council , Biomedical Catalyst. 2021. Available from: https://mrc.ukri.org/funding/science-areas/translation/biomedical-catalyst/
- Nandakumar R, Gollakota S, Sunshine JE. Opioid overdose detection using smartphones. Sci Transl Med. 2019 Jan 9;11(474). pii: eaau8914. doi: 10.1126/scitranslmed.aau8914.
- Nandakumar R., Gollakota S.,Sunshine J.E. (2019) Science Translational Medicine: 11; eaau8914 Available online at: https://stm.sciencemag.org/content/11/474/eaau8914
- National Institute for Drug Abuse (2017) Naloxone for Opioid Overdose: Life Saving Science. Available online at: https://www.drugabuse.gov/publications/naloxone-opioid-overdose-life-saving-science/naloxone-opioid-overdose-life-saving-science
- National records of Scotland, National Statistics. Drug-related deaths in Scotland in 2019, published 15/12/2020. Available from https://www.nrscotland.gov.uk/, accessed 09/02/2020.
- Scottish Government. Evidence=-Based Strategies for Preventing Drug-Related Deaths in Scotland, Our Emergency Response. January 2020. Available from https://www.gov.scot/. Accessed 10/02/2021
- United Nations Office of Drugs and Crime. World Drug Report 2020 Booklet 1. Available from https://wdr.unodc.org/, Accessed 10/02/2021.
- Winhusen T, Theobald J, Lewis D, Wilder CM, Lyons MS. Development and initial testing of a tailored telephone intervention delivered by peers to prevent recurring opioid-overdoses (TTIP-PRO). Health Educ Res. 2016 Apr;31(2):146-60. doi: 10.1093/her/cyw010.
- World Health Organisation. Opioid overdose. August 2020. Available from: https://www.who.int/, Accessed 10/02/2021
- INGN21RM077